Animal models have proven unreliable for testing biologics, yet non-animal methodologies remain underutilised in India's pharmaceutical sector. In light of this, critically examine the opportunities and challenges in integrating Non-Animal Methodologies (NAMs) into India's biologics and biosimilars ecosystem, with reference to the Biopharma SHAKTI strategy.

Question

PocketIAS · Accepted Answer

Introduction

With biologics driving over 30% of global pharma value, the limits of animal models—especially for complex, human-specific pathways—are evident. India’s push under Biopharma SHAKTI (DBT-BIRAC) creates an opportunity to mainstream Non-Animal Methodologies (NAMs), but adoption remains nascent.

Body

NAMs—such as organoids, organ-on-chip systems, in silico modelling, and high-throughput cell assays—offer clear advantages for biologics and biosimilars. They improve human relevance, enable mechanism-specific toxicity testing, and reduce time and costs in development. For biosimilars, NAMs can strengthen comparability exercises (analytical + functional assays), aligning with global regulatory shifts (e.g., US FDA Modernization Act 2.0, 2022). Under Biopharma SHAKTI, investments in biologics manufacturing, translational research, and skill development can dovetail with NAM infrastructure, positioning India as a cost-efficient, innovation-driven hub. Ethically, NAMs also align with the 3Rs principle (Replace, Reduce, Refine) and evolving CPCSEA norms.

However, challenges are significant. Regulatory acceptance by CDSCO remains cautious, with limited formal pathways for NAM-based evidence in biologics approval. High capital costs, lack of standardisation and validation, and dependence on imported technologies constrain scale-up. Skill gaps in computational biology and advanced tissue engineering persist. Moreover, fragmented coordination between academia, startups, CROs, and regulators slows translation. For complex biologics, complete replacement of animal studies is still scientifically contested in certain contexts.

Conclusion / Way Forward

Integrating NAMs requires a mission-mode approach: clear regulatory guidance and validation frameworks, dedicated NAM centres of excellence under Biopharma SHAKTI, public–private partnerships, and global harmonisation with OECD/FDA standards. Coupled with targeted skilling and incentives, India can transition from a generics powerhouse to a next-generation biologics innovator, while ensuring ethical and scientifically robust drug development.

✍️ Practice Mode

Write. Evaluate. Improve. Repeat.

The model answer is ready.

Comments (0)